Atsuo Ueda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Atsuo Ueda has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Hiromichi Suzuki
Department of Infectious Diseases, University of Tsukuba Hospital, Tsukuba, Japan
11 shared publications - Yusaku Akashi
Department of Infectious Diseases, Faculty of Medicine, University of Tsukuba
11 shared publications - Koji Nakamura
Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki, 305-8558, Japan
10 shared publications - Shigeyuki Notake
Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki, 3058558, Japan
10 shared publications - Yuto Takeuchi
Department of Infectious Diseases, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki, 305-8576, Japan; Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, 1-3-1 Amakubo Tsukuba, Ibaraki, 305-8558, Japan
10 shared publications - Yoshihiko Kiyasu
Department of Infectious Diseases, University of Tsukuba Hospital, Japan
7 shared publications
Latest Publications
- Open Access
- 7 March 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (7) , 654-659
Prospective study of three saliva qualitative antigen testing kits for the detection of SARS-CoV-2 among mainly symptomatic patients in Japan
- 7 March 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (7) , 654-659
Open AccessProspective study of three saliva qualitative antigen testing kits for the detection of SARS-CoV-2 among mainly symptomatic patients in Japan
- Open Access
A prospective evaluation of three saliva qualitative antigen testing kits for the detection of SARS-CoV-2 in Japan
Introduction Rapid qualitative antigen testing has been widely used for the laboratory diagnosis of COVID-19 with nasopharyngeal samples. Saliva samples have been used as alternative samples, but the analytical performance of those samples for qualitative antigen testing has not been sufficiently evaluated. Methods A prospective observational study evaluated the analytical performance of three In Vitro Diagnostics (IVD) approved COVID-19 rapid antigen detection kits for saliva between June 2022 and July 2022 in Japan using real-time reverse transcription polymerase chain reaction (RT-PCR) as a reference. A nasopharyngeal sample and a saliva sample were simultaneously obtained, and RT-PCR was performed. Results In total, saliva samples and nasopharyngeal samples were collected from 471 participants (140 RT-PCR-positive saliva samples and 143 RT-PCR-positive nasopharyngeal samples) for the analysis. The median Ct values were 25.5 (interquartile range [IQR]: 21.9-28.8) for saliva samples and 17.1 (IQR: 15.5-18.7) for nasopharyngeal samples (p90% for saliva samples with a moderate-to-high viral load (CtConclusion COVID-19 rapid antigen detection kits with saliva showed high specificities, but the sensitivities varied among kits, and the analytical performance of saliva qualitative antigen detection kits was much worse than that of kits using nasopharyngeal samples.
Open AccessA prospective evaluation of three saliva qualitative antigen testing kits for the detection of SARS-CoV-2 in Japan
Introduction Rapid qualitative antigen testing has been widely used for the laboratory diagnosis of COVID-19 with nasopharyngeal samples. Saliva samples have been used as alternative samples, but the analytical performance of those samples for qualitative antigen testing has not been sufficiently evaluated. Methods A prospective observational study evaluated the analytical performance of three In Vitro Diagnostics (IVD) approved COVID-19 rapid antigen detection kits for saliva between June 2022 and July 2022 in Japan using real-time reverse transcription polymerase chain reaction (RT-PCR) as a reference. A nasopharyngeal sample and a saliva sample were simultaneously obtained, and RT-PCR was performed. Results In total, saliva samples and nasopharyngeal samples were collected from 471 participants (140 RT-PCR-positive saliva samples and 143 RT-PCR-positive nasopharyngeal samples) for the analysis. The median Ct values were 25.5 (interquartile range [IQR]: 21.9-28.8) for saliva samples and 17.1 (IQR: 15.5-18.7) for nasopharyngeal samples (p90% for saliva samples with a moderate-to-high viral load (CtConclusion COVID-19 rapid antigen detection kits with saliva showed high specificities, but the sensitivities varied among kits, and the analytical performance of saliva qualitative antigen detection kits was much worse than that of kits using nasopharyngeal samples.
- Open Access
- 20 November 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (3) , 257-262
Analytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant
- 20 November 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (3) , 257-262
Open AccessAnalytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant
- 7 April 2022
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 26 (3) , 323-331
Clinical Performance of the cobas Liat SARS-CoV-2 & Influenza A/B Assay in Nasal Samples
Background and Objective Point-of-care type molecular diagnostic tests have been used for detecting SARS-CoV-2, although their clinical utility with nasal samples has yet to be established. This study evaluated the clinical performance of the cobas Liat SARS-CoV-2 & Influenza A/B (Liat) assay in nasal samples. Methods Nasal and nasopharyngeal samples were collected and were tested using the Liat, the cobas 6800 system and the cobas SARS-CoV-2 & Influenza A/B (cobas), and a method developed by National Institute of Infectious Diseases, Japan (NIID). Results A total of 814 nasal samples were collected. The Liat assay was positive for SARS-CoV-2 in 113 (13.9%). The total, positive, and negative concordance rate between the Liat and cobas/NIID assays were 99.3%/98.4%, 99.1%/100%, and 99.3%/98.2%, respectively. Five samples were positive only using the Liat assay. Their Ct values ranged from 31.9 to 37.2. The Ct values of the Liat assay were significantly lower (p < 0.001) but were correlated (p < 0.001) with those of other molecular assays. In the participants who tested positive for SARS-CoV-2 on the Liat assay using nasopharyngeal samples, 88.2% of their nasal samples also tested positive using the Liat assay. Conclusion The Liat assay showed high concordance with other molecular assays in nasal samples. Some discordance occurred in samples with Ct values > 30 on the Liat assay.
- 7 April 2022
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 26 (3) , 323-331
Clinical Performance of the cobas Liat SARS-CoV-2 & Influenza A/B Assay in Nasal Samples
Background and Objective Point-of-care type molecular diagnostic tests have been used for detecting SARS-CoV-2, although their clinical utility with nasal samples has yet to be established. This study evaluated the clinical performance of the cobas Liat SARS-CoV-2 & Influenza A/B (Liat) assay in nasal samples. Methods Nasal and nasopharyngeal samples were collected and were tested using the Liat, the cobas 6800 system and the cobas SARS-CoV-2 & Influenza A/B (cobas), and a method developed by National Institute of Infectious Diseases, Japan (NIID). Results A total of 814 nasal samples were collected. The Liat assay was positive for SARS-CoV-2 in 113 (13.9%). The total, positive, and negative concordance rate between the Liat and cobas/NIID assays were 99.3%/98.4%, 99.1%/100%, and 99.3%/98.2%, respectively. Five samples were positive only using the Liat assay. Their Ct values ranged from 31.9 to 37.2. The Ct values of the Liat assay were significantly lower (p < 0.001) but were correlated (p < 0.001) with those of other molecular assays. In the participants who tested positive for SARS-CoV-2 on the Liat assay using nasopharyngeal samples, 88.2% of their nasal samples also tested positive using the Liat assay. Conclusion The Liat assay showed high concordance with other molecular assays in nasal samples. Some discordance occurred in samples with Ct values > 30 on the Liat assay.
- Open Access
- 7 March 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (6) , 840-843
A prospective evaluation of diagnostic performance of a combo rapid antigen test QuickNavi-Flu+COVID19 Ag
- 7 March 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (6) , 840-843
Open AccessA prospective evaluation of diagnostic performance of a combo rapid antigen test QuickNavi-Flu+COVID19 Ag
- 24 February 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (6) , 780-785
A prospective clinical evaluation of the diagnostic accuracy of the SARS-CoV-2 rapid antigen test using anterior nasal samples
- 24 February 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (6) , 780-785
A prospective clinical evaluation of the diagnostic accuracy of the SARS-CoV-2 rapid antigen test using anterior nasal samples
- Open Access
- 31 December 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (4) , 543-547
Clinical evaluation of the rapid nucleic acid amplification point-of-care test (Smart Gene SARS-CoV-2) in the analysis of nasopharyngeal and anterior nasal samples
- 31 December 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (4) , 543-547
Open AccessClinical evaluation of the rapid nucleic acid amplification point-of-care test (Smart Gene SARS-CoV-2) in the analysis of nasopharyngeal and anterior nasal samples
- 10 November 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (2) , 248-251
Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2
- 10 November 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (2) , 248-251
Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2
- 27 October 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (1) , 78-81
Diagnostic performance of a novel digital immunoassay (RapidTesta SARS-CoV-2): A prospective observational study with nasopharyngeal samples
- 27 October 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (1) , 78-81
Diagnostic performance of a novel digital immunoassay (RapidTesta SARS-CoV-2): A prospective observational study with nasopharyngeal samples
- Open Access
- 1 June 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (6) , 890-894
The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan
- 1 June 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (6) , 890-894
Open AccessThe evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan